Search Results

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, announced that CEO Vimal Mehta, Ph.D., will present at the Jefferies Global Healthcare Conference in New York City.

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, announced its financial results for the first quarter of 2024.

BioXcel Therapeutics, Inc. announced that Rob Risinger, M.D., Chief Medical Officer of Neuroscience, will deliver oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.

BioXcel Therapeutics, Inc. today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets.

BioXcel Therapeutics, Inc. provided an update on its late-stage TRANQUILITY and SERENITY clinical programs.

BioXcel Therapeutics, Inc. today announced positive topline results from a post-marketing requirement (PMR) study of IGALMI™ (dexmedetomidine) sublingual film that demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose after seven days of PRN (as-needed) treatment.

BioXcel Therapeutics, Inc. announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares of common stock, par value $0.001 per share, and accompanying warrants to purchase up to 3,054,609 shares of Common Stock at a combined offering price of $2.901 per Share.